

EXHIBIT D

Display Settings: Summary, 20 per page, Sorted by Recently Added

Results: 1 to 20 of 86

1. [Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.](#)
Zielinski R, Lyakhov I, Jacobs A, Chertov O, Kramer-Marek G, Francella N, Stephen A, Fisher R, Blumenthal R, Capala J. *J Immunother.* 2009 Oct;32(8):817-25.
PMID: 19752752 [PubMed - in process]
2. [An internalizing antibody specific for the human asialoglycoprotein receptor.](#)
Trachtenherts A, Benhar I. *Hybridoma (Larchmt).* 2009 Aug;28(4):225-33.
PMID: 19663694 [PubMed - indexed for MEDLINE]
3. [Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes.](#)
Gao J, Zhong W, He J, Li H, Zhang H, Zhou G, Li B, Lu Y, Zou H, Kou G, Zhang D, Wang H, Guo Y, Zhong Y. *Int J Pharm.* 2009 Jun 5;374(1-2):145-52. Epub 2009 Mar 24.
PMID: 19446771 [PubMed - indexed for MEDLINE]
4. [Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.](#)
Kreitman RJ. *BioDrugs.* 2009;23(1):1-13. doi: 10.2165/00063030-200923010-00001. Review.
PMID: 19344187 [PubMed - indexed for MEDLINE] [Free PMC Article](#) [Free text](#)
5. [Combination therapy using three novel prolactin receptor antagonist-based fusion proteins effectively inhibits tumor recurrence and metastasis in HER2/neu transgenic mice.](#)
Tombllyn S, Springs AE, Langenheim JF, Chen WY. *Int J Oncol.* 2009 Apr;34(4):1139-46.
PMID: 19287973 [PubMed - indexed for MEDLINE]
6. [Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly\(lactic-co-glycolic acid\) nanoparticles conjugated with humanized SM5-1 F\(ab'\) fragments.](#)
Gao J, Kou G, Chen H, Wang H, Li B, Lu Y, Zhang D, Wang S, Hou S, Qian W, Dai J, Zhao J, Zhong Y, Guo Y. *Mol Cancer Ther.* 2008 Oct;7(10):3399-407.
PMID: 18852143 [PubMed - indexed for MEDLINE] [Free Article](#)
7. [Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts.](#)
Klechevsky E, Gallegos M, Denkberg G, Palucka K, Banchereau J, Cohen C, Reiter Y. *Cancer Res.* 2008 Aug 1;68(15):6360-7.
PMID: 18676861 [PubMed - indexed for MEDLINE] [Free PMC Article](#) [Free text](#)
8. [PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity.](#)
Gao J, Kou G, Wang H, Chen H, Li B, Lu Y, Zhang D, Wang S, Hou S, Qian W, Dai J, Zhao J, Zhong Y, Guo Y. *Breast Cancer Res Treat.* 2009 May;115(1):29-41. Epub 2008 May 15.
PMID: 18481173 [PubMed - indexed for MEDLINE]
9. [Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.](#)
Chen H, Gao J, Lu Y, Kou G, Zhang H, Fan L, Sun Z, Guo Y, Zhong Y. *J Control Release.* 2008 Jun 24;128(3):209-16. Epub 2008 Mar 19.
PMID: 18450313 [PubMed - indexed for MEDLINE]
10. [Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated *Pseudomonas exotoxin A*.](#)
Wang H, Dai J, Li B, Fan K, Peng L, Zhang D, Cao Z, Qian W, Wang H, Zhao J, Guo Y. *Protein Expr Purif.* 2008 Mar;58(1):140-7. Epub 2007 Sep 19.
PMID: 17950620 [PubMed - indexed for MEDLINE]
11. [Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.](#)
Powell DJ Jr, Felipe-Silva A, Merino MJ, Ahmadzadeh M, Allen T, Levy C, White DE, Mavroukakis S, Kreitman RJ, Rosenberg SA, Pastan I. *J Immunol.* 2007 Oct 1;179(7):4919-28.
PMID: 17878392 [PubMed - indexed for MEDLINE] [Free PMC Article](#) [Free text](#)
12. [EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells.](#)
Ochiai H, Archer GE, Herndon JE 2nd, Kuan CT, Mitchell DA, Bigner DD, Pastan IH, Sampson JH. *Cancer Immunol Immunother.* 2008 Jan;57(1):115-21. Epub 2007 Jul 19.
PMID: 17634939 [PubMed - indexed for MEDLINE] [Free PMC Article](#) [Free text](#)
13. [Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak](#)

syndrome.

Wang H, Song S, Kou G, Li B, Zhang D, Hou S, Qian W, Dai J, Tian L, Zhao J, Guo Y.
Cancer Immunol Immunother. 2007 Nov;56(11):1775-83. Epub 2007 Apr 13.
PMID: 17431617 [PubMed - indexed for MEDLINE]

14. Immunotoxins in the treatment of refractory hairy cell leukemia.

Kreitman RJ, Pastan I.
Hematol Oncol Clin North Am. 2006 Oct;20(5):1137-51, viii. Review.
PMID: 16990113 [PubMed - indexed for MEDLINE]

15. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.

Attia P, Powell DJ Jr, Maker AV, Kreitman RJ, Pastan I, Rosenberg SA.
J Immunother. 2006 Mar-Apr;29(2):208-14.
PMID: 16531821 [PubMed - indexed for MEDLINE] Free PMC Article Free text

16. Rapid downregulation of beta-actin-based CAG promoter and filamentous actin in injured podocytes.

Asano T, Matsusaka T, Mizutani S, Ichikawa I.
J Med Dent Sci. 2005 Jun;52(2):129-34.
PMID: 16189885 [PubMed - indexed for MEDLINE]

17. CLL immunotoxins.

Frankel AE, Kreitman RJ.
Leuk Res. 2005 Sep;29(9):985-6. Epub 2005 Mar 17.
PMID: 16038723 [PubMed - indexed for MEDLINE]

18. Preparation and characterization of fusion protein truncated Pseudomonas Exotoxin A (PE38KDEL) in Escherichia coli.

Song S, Xue J, Fan K, Kou G, Zhou Q, Wang H, Guo Y.
Protein Expr Purif. 2005 Nov;44(1):52-7.
PMID: 15922623 [PubMed - indexed for MEDLINE]

19. Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury.

Matsusaka T, Xin J, Niwa S, Kobayashi K, Akatsuka A, Hashizume H, Wang QC, Pastan I, Fogo AB, Ichikawa I.
J Am Soc Nephrol. 2005 Apr;16(4):1013-23. Epub 2005 Mar 9.
PMID: 15758046 [PubMed - indexed for MEDLINE] Free Article

20. Construction and expression of novel immunotoxin cplI-4(13D)-PE38KDEL with increased activity.

Cui JX, Ji JF, Lv AG, Wu WF.
Biochemistry (Mosc). 2005 Jan;70(1):62-8.
PMID: 15701050 [PubMed - indexed for MEDLINE]

Display Settings: Summary, 20 per page, Sorted by Recently Added

Results: 21 to 40 of 86

21. [Hodgkin lymphoma therapy with interleukin-4 receptor-directed cytotoxin in an infiltrating animal model.](#)
Kawakami M, Kawakami K, Kioi M, Leland P, Puri RK.
Blood. 2005 May 1;105(9):3707-13. Epub 2004 Dec 30.
PMID: 15626735 [PubMed - indexed for MEDLINE] [Free PMC Article](#) [Free text](#)
22. [Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.](#)
Beseth BD, Cameron RB, Leland P, You L, Varricchio F, Kreitman RJ, Maki RA, Jablons DM, Husain SR, Puri RK.
Ann Thorac Surg. 2004 Aug;78(2):436-43; discussion 436-43.
PMID: 15276492 [PubMed - indexed for MEDLINE]
23. [Gateways to clinical trials.](#)
Bayés M, Rabasseda X, Prous JR.
Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44.
PMID: 15148527 [PubMed - indexed for MEDLINE]
24. [Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy.](#)
Kawakami M, Kawakami K, Puri RK.
J Neurooncol. 2003 Oct;65(1):15-25. Review.
PMID: 14649882 [PubMed - indexed for MEDLINE]
25. [Multidrug-resistant tumor cells remain sensitive to a recombinant interleukin-4-Pseudomonas exotoxin, except when overexpressing the multidrug resistance protein MRP1.](#)
de Jong MC, Scheffer GL, Broxterman HJ, Hooijberg JH, Slootstra JW, Meloen RH, Kreitman RJ, Husain SR, Joshi BH, Puri RK, Schepers RJ.
Clin Cancer Res. 2003 Oct 15;9(13):5009-17.
PMID: 14581376 [PubMed - indexed for MEDLINE] [Free Article](#)
26. [IL-4 receptor-directed cytotoxin for therapy of AIDS-associated KS tumors.](#)
Puri RK.
Drug News Perspect. 2000 Sep;13(7):395-402.
PMID: 12937611 [PubMed]
27. [Immunobiological treatments of hairy-cell leukaemia.](#)
Kreitman RJ, Pastan I.
Best Pract Res Clin Haematol. 2003 Mar;16(1):117-33. Review.
PMID: 12670470 [PubMed - indexed for MEDLINE]
28. [Interleukin-4 receptor-targeted cytotoxin therapy of androgen-dependent and -independent prostate carcinoma in xenograft models.](#)
Husain SR, Kawakami K, Kawakami M, Puri RK.
Mol Cancer Ther. 2003 Mar;2(3):245-54.
PMID: 12657719 [PubMed - indexed for MEDLINE] [Free Article](#)
29. [\[Synergistic cytotoxic effect of immunotoxin HEL-PE38KDEL and cis-platin against tumor cells\]](#)
Wang JS, Wang SM, Chen GR, Yang DJ.
Ai Zheng. 2002 Apr;21(4):360-3. Chinese.
PMID: 12452011 [PubMed - indexed for MEDLINE]
30. [Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy.](#)
Kawakami M, Kawakami K, Stepensky VA, Maki RA, Robin H, Muller W, Husain SR, Puri RK.
Clin Cancer Res. 2002 Nov;8(11):3503-11.
PMID: 12429641 [PubMed - indexed for MEDLINE] [Free Article](#)
31. [IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein.](#)
Joshi BH, Leland P, Silber J, Kreitman RJ, Pastan I, Berger M, Puri RK.
Br J Cancer. 2002 Jan 21;86(2):285-91.
PMID: 11870521 [PubMed - indexed for MEDLINE] [Free PMC Article](#) [Free text](#)
32. [Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides.](#)
Decker T, Hipp S, Kreitman RJ, Pastan I, Peschel C, Licht T.
Blood. 2002 Feb 15;99(4):1320-6.
PMID: 11830482 [PubMed - indexed for MEDLINE] [Free Article](#)
33. [Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models.](#)

- Strome SE, Kawakami K, Alejandro D, Voss S, Kasperbauer JL, Salomao D, Chen L, Maki RA, Puri RK.
Clin Cancer Res. 2002 Jan;8(1):281-6.
PMID: 11801570 [PubMed - indexed for MEDLINE] Free Article
34. Internalization property of interleukin-4 receptor alpha chain increases cytotoxic effect of interleukin-4 receptor-targeted cytotoxin in cancer cells.
Kawakami K, Kawakami M, Leland P, Puri RK.
Clin Cancer Res. 2002 Jan;8(1):258-66.
PMID: 11801567 [PubMed - indexed for MEDLINE] Free Article
35. Biologic therapy for psoriasis: a brief history, I.
Tutrone WD, Kagen MH, Barbagallo J, Weinberg JM.
Cutis. 2001 Nov;68(5):331-6. Review.
PMID: 11766118 [PubMed - indexed for MEDLINE]
36. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures.
Joshi BH, Leland P, Asher A, Prayson RA, Varricchio F, Puri RK.
Cancer Res. 2001 Nov 15;61(22):8058-61.
PMID: 11719427 [PubMed - indexed for MEDLINE] Free Article
37. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy.
Kawakami K, Kawakami M, Puri RK.
Crit Rev Immunol. 2001;21(1-3):299-310. Review.
PMID: 11642612 [PubMed - indexed for MEDLINE]
38. Cytotoxins directed at interleukin-4 receptors as therapy for human brain tumors.
Puri RK.
Methods Mol Biol. 2001;166:155-76. Review. No abstract available.
PMID: 11217365 [PubMed - indexed for MEDLINE]
39. Quantification of immunotoxin number for complete therapeutic response.
Kreitman RJ.
Methods Mol Biol. 2001;166:111-23. Review. No abstract available.
PMID: 11217362 [PubMed - indexed for MEDLINE]
40. Inhibition of TNF-alpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38-LMB-2.
Onda M, Willingham M, Wang QC, Kreitman RJ, Tsutsumi Y, Nagata S, Pastan I.
J Immunol. 2000 Dec 15;165(12):7150-6.
PMID: 11120846 [PubMed - indexed for MEDLINE] Free Article

Display Settings: Summary, 20 per page, Sorted by Recently Added

Results: 41 to 60 of 86

41. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein *in vitro* and *in vivo*.
Leland P, Taguchi J, Husain SR, Kreitman RJ, Pastan I, Puri RK.
Mol Med. 2000 Mar;6(3):165-78.
PMID: 10965493 [PubMed - indexed for MEDLINE] [Free PMC Article](#) [Free text](#)
42. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.
Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK.
Clin Cancer Res. 2000 Jun;6(6):2157-65.
PMID: 10873064 [PubMed - indexed for MEDLINE] [Free Article](#)
43. Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells.
Kawakami K, Leland P, Puri RK.
Cancer Res. 2000 Jun 1;60(11):2981-7.
PMID: 10850446 [PubMed - indexed for MEDLINE] [Free Article](#)
44. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC, FitzGerald DJ, Pastan I.
Clin Cancer Res. 2000 Apr;6(4):1476-87.
PMID: 10778980 [PubMed - indexed for MEDLINE] [Free Article](#)
45. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, Waldmann TA, Pastan I.
J Clin Oncol. 2000 Apr;18(8):1622-36.
PMID: 10764422 [PubMed - indexed for MEDLINE]
46. Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the alpha(2)-macroglobulin receptor.
Rajagopal V, Kreitman RJ.
J Biol Chem. 2000 Mar 17;275(11):7566-73.
PMID: 10713063 [PubMed - indexed for MEDLINE] [Free Article](#)
47. Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2).
Robbins DH, Margulies I, Stetler-Stevenson M, Kreitman RJ.
Clin Cancer Res. 2000 Feb;6(2):693-700.
PMID: 10690555 [PubMed - indexed for MEDLINE] [Free Article](#)
48. First responses seen in cancer patients to a recombinant immunotoxin.
Kuska B.
J Natl Cancer Inst. 1999 Dec 1;91(23):1997. No abstract available.
PMID: 10580021 [PubMed - indexed for MEDLINE] [Free Article](#)
49. Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point.
Onda M, Kreitman RJ, Vasmatzis G, Lee B, Pastan I.
J Immunol. 1999 Dec 1;163(11):6072-7.
PMID: 10570296 [PubMed - indexed for MEDLINE] [Free Article](#)
50. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model.
Husain SR, Kreitman RJ, Pastan I, Puri RK.
Nat Med. 1999 Jul;5(7):817-22.
PMID: 10395328 [PubMed - indexed for MEDLINE]
51. Targeting AIDS-Kaposi's sarcoma.
Mesri EA.
Nat Med. 1999 Jul;5(7):738-9. No abstract available.
PMID: 10395315 [PubMed - indexed for MEDLINE]
52. Recombinant oncotoxin AR209 (anti-P185erbB-2) diminishes human prostate carcinoma xenografts.
Skrepnick N, Zieske AW, Bravo JC, Gillespie AT, Hunt JD.
J Urol. 1999 Mar;161(3):984-9.
PMID: 10022738 [PubMed - indexed for MEDLINE]
53. Aggressive administration of recombinant oncotoxin AR209 (anti-ErbB-2) in athymic nude mice implanted with orthotopic human non-small cell lung tumours.

- Skrepnik N, Zieske AW, Robert E, Bravo JC, Mera R, Hunt JD.
Eur J Cancer. 1998 Sep;34(10):1628-33.
PMID: 9893641 [PubMed - indexed for MEDLINE]
54. Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy.
Husain SR, Behari N, Kreitman RJ, Pastan I, Puri RK.
Cancer Res. 1998 Aug 15;58(16):3649-53.
PMID: 9721874 [PubMed - indexed for MEDLINE] Free Article
55. Anti-prostate immunotoxins: cytotoxicity of E4 antibody-Pseudomonas exotoxin constructs.
Essand M, Pastan I.
Int J Cancer. 1998 Jul 3;77(1):123-7.
PMID: 9639403 [PubMed - indexed for MEDLINE]
56. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
Yang D, Kuan CT, Payne J, Kihara A, Murray A, Wang LM, Alimandi M, Pierce JH, Pastan I, Lippman ME.
Clin Cancer Res. 1998 Apr;4(4):993-1004.
PMID: 9563895 [PubMed - indexed for MEDLINE] Free Article
57. Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells.
Kreitman RJ, Pastan I.
Blood. 1997 Jul 1;90(1):252-9.
PMID: 9207460 [PubMed - indexed for MEDLINE] Free Article
58. Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin.
Husain SR, Gill P, Kreitman RJ, Pastan I, Puri RK.
Mol Med. 1997 May;3(5):327-38.
PMID: 9205948 [PubMed - indexed for MEDLINE] Free PMC Article Free text
59. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma.
Puri RK, Hoon DS, Leland P, Snoy P, Rand RW, Pastan I, Kreitman RJ.
Cancer Res. 1996 Dec 15;56(24):5631-7.
PMID: 8971168 [PubMed - indexed for MEDLINE] Free Article
60. Effects of anti-erbB-2 (HER-2/neu) recombinant oncotoxin AR209 on human non-small cell lung carcinoma grown orthotopically in athymic nude mice.
Skrepnik N, Araya JC, Qian Z, Xu H, Hamide J, Mera R, Hunt JD.
Cin Cancer Res. 1996 Nov;2(11):1851-7.
PMID: 9816140 [PubMed - indexed for MEDLINE] Free Article

Display Settings: Summary, 20 per page, Sorted by Recently Added

Results: 61 to 80 of 86

61. [Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies.](#)
Mansfield E, Pastan I, Fitzgerald DJ.
Bioconjug Chem. 1996 Sep-Oct;7(5):557-63.
PMID: 8889017 [PubMed - indexed for MEDLINE]
62. [An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity.](#)
Puri RK, Leland P, Obiri NI, Husain SR, Mule J, Pastan I, Kreitman RJ.
Cell Immunol. 1996 Jul 10;171(1):80-6.
PMID: 8660841 [PubMed - indexed for MEDLINE]
63. [Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice.](#)
Reiter Y, Wright AF, Tonge DW, Pastan I.
Int J Cancer. 1996 Jul 3;67(1):113-23.
PMID: 8690511 [PubMed - indexed for MEDLINE]
64. [Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploididentical bone marrow transplantation.](#)
Mavroudis DA, Jiang YZ, Hensel N, Lewalle P, Couriel D, Kreitman RJ, Pastan I, Barrett AJ.
Bone Marrow Transplant. 1996 May;17(5):793-9.
PMID: 8733700 [PubMed - indexed for MEDLINE]
65. [Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation.](#)
Kuan CT, Pastan I.
Biochemistry. 1996 Mar 5;35(9):2872-7.
PMID: 8608123 [PubMed - indexed for MEDLINE]
66. [Activity of anti-erbB-2 recombinant toxin OLX-209 on lung cancer cell lines in the absence of erbB-2 gene amplification.](#)
Kasprzyk PG, Sullivan TL, Hunt JD, Gubish CT, Scoppa CA, Oelkult M, Bird R, Fischer PH, Siegfried JM, King CR.
Clin Cancer Res. 1996 Jan;2(1):75-80.
PMID: 9816093 [PubMed - indexed for MEDLINE] [Free Article](#)
67. [Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma.](#)
Kreitman RJ, Puri RK, Pastan I.
Cancer Res. 1995 Aug 1;55(15):3357-63.
PMID: 7614471 [PubMed - indexed for MEDLINE] [Free Article](#)
68. [Cytotoxic activity of chimeric toxins containing the epidermal growth factor-like domain of heregulins fused to PE38KDEL, a truncated recombinant form of Pseudomonas exotoxin.](#)
Kihara A, Pastan I.
Cancer Res. 1995 Jan 1;55(1):71-7.
PMID: 7805044 [PubMed - indexed for MEDLINE] [Free Article](#)
69. [Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment.](#)
Reiter Y, Brinkmann U, Jung SH, Lee B, Kasprzyk PG, King CR, Pastan I.
J Biol Chem. 1994 Jul 15;269(28):18327-31.
PMID: 7913461 [PubMed - indexed for MEDLINE]
70. [Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.](#)
Reiter Y, Kreitman RJ, Brinkmann U, Pastan I.
Int J Cancer. 1994 Jul 1;58(1):142-9.
PMID: 8014011 [PubMed - indexed for MEDLINE]
71. [Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.](#)
Reiter Y, Pai LH, Brinkmann U, Wang QC, Pastan I.
Cancer Res. 1994 May 15;54(10):2714-8.
PMID: 8168102 [PubMed - indexed for MEDLINE] [Free Article](#)
72. [Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions.](#)
Reiter Y, Brinkmann U, Kreitman RJ, Jung SH, Lee B, Pastan I.
Biochemistry. 1994 May 10;33(18):5451-9.
PMID: 7910034 [PubMed - indexed for MEDLINE]

73. [Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv.](#)
Reiter Y, Brinkmann U, Webber KO, Jung SH, Lee B, Pastan I.
Protein Eng. 1994 May;7(5):697-704.
PMID: 8073039 [PubMed - indexed for MEDLINE]
74. [Recombinant immunotoxins containing anti-Tac\(Fv\) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma.](#)
Kreitman RJ, Bailon P, Chaudhary VK, FitzGerald DJ, Pastan I.
Blood. 1994 Jan 15;83(2):426-34.
PMID: 8286741 [PubMed - indexed for MEDLINE] [Free Article](#)
75. [A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.](#)
Brinkmann U, Reiter Y, Jung SH, Lee B, Pastan I.
Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7538-42.
PMID: 8356052 [PubMed - indexed for MEDLINE] [Free PMC Article](#) [Free text](#)
76. [Recombinant immunotoxins containing the VH or VL domain of monoclonal antibody B3 fused to Pseudomonas exotoxin.](#)
Brinkmann U, Lee BK, Pastan I.
J Immunol. 1993 Apr 1;150(7):2774-82.
PMID: 8454854 [PubMed - indexed for MEDLINE]
77. [Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds.](#)
Kreitman RJ, Batra JK, Seetharam S, Chaudhary VK, FitzGerald DJ, Pastan I.
Bioconjug Chem. 1993 Mar-Apr;4(2):112-20.
PMID: 7873642 [PubMed - indexed for MEDLINE]
78. [Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice.](#)
Kreitman RJ, Hansen HJ, Jones AL, FitzGerald DJ, Goldenberg DM, Pastan I.
Cancer Res. 1993 Feb 15;53(4):819-25.
PMID: 8428363 [PubMed - indexed for MEDLINE] [Free Article](#)
79. [A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of Pseudomonas exotoxin.](#)
Brinkmann U, Gallo M, Brinkmann E, Kunwar S, Pastan I.
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):547-51.
PMID: 8421689 [PubMed - indexed for MEDLINE] [Free PMC Article](#) [Free text](#)
80. [Affinity purification and characterization of anti-Tac\(Fv\)-C3-PE38KDEL: A highly potent cytotoxic agent specific to cells bearing IL-2 receptors.](#)
Spence C, Nachman M, Gately MK, Kreitman RJ, Pastan I, Bailon P.
Bioconjug Chem. 1993 Jan-Feb;4(1):63-8.
PMID: 8431514 [PubMed - indexed for MEDLINE]

Display Settings: Summary, 20 per page, Sorted by Recently Added

Results: 12

1. [Molecular construction and characterization of a novel exotoxin fusion protein that selectively blocks the B7:CD28 costimulatory signal system.](#)
Xi Y, Yuan Z, Zhang H, Guan H, Kong F, Liu N, Liang F, Cui J, Guo S, Sun Y, Xi C.
J Immunother. 2006 Nov-Dec;29(6):586-95.
PMID: 17063121 [PubMed - indexed for MEDLINE]
2. [\[Establishment of purification procedure for recombinant fusion protein B7-2-PE40KDEL\]](#)
Guan HR, Sun YY, Yuan ZH, Zhang HL, Liang F, Liu N, Guo SQ, Xi CX, Xi YZ.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Feb;14(1):123-7. Chinese.
PMID: 16584607 [PubMed - indexed for MEDLINE]
3. [\[Biochemical and physical properties for a recombinant IL6 Pseudomonas exotoxin fusion protein IL6D24-PE40KDEL\]](#)
Cui JW, Guo SQ, Sun YY, Liu N, Liang F, Xi YZ.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2004 Dec;12(6):825-8. Chinese.
PMID: 15631670 [PubMed - indexed for MEDLINE]
4. [\[Molecular design and construction of IL6D24-PE40KDEL, a novel recombinant interleukin6-pseudomonas exotoxin fusion protein, having targeted cytotoxicity for leukemias expressing interleukin6 receptors\]](#)
Zheng LY, Xi YZ, Kong FH, Cui JW, Liang F, Liu N, Sun YY, Guo SQ.
Zhonghua Yi Xue Za Zhi. 2003 Jul 25;83(14):1246-50. Chinese.
PMID: 12930640 [PubMed - indexed for MEDLINE]
5. [\[Construction, bioactivity identification and structural characteristics analysis of a novel recombinant immunosuppression protein B7-2-L-PE40KDEL\]](#)
Yuan Z, Xi Y, Zhang H, Kong F, Guan H, Guo S, Liu N, Liang F, Sun Y, Cui J.
Zhonghua Yi Xue Za Zhi. 2002 Nov 25;82(22):1541-5. Chinese.
PMID: 12609063 [PubMed - indexed for MEDLINE]
6. [Augmentation of the activity of an immunotoxin, anti-Tac\(Fv\)-PE40KDEL, in T cell lines infected with human T cell leukemia virus type-I.](#)
Ohno N, Kreitman RJ, Saito T, Masamoto I, Uozumi K, Hanada S, Takeuchi S, Furukawa T, Sumizawa T, Arima T, Akiyama S.
Leuk Lymphoma. 2002 Apr;43(4):885-8.
PMID: 12153180 [PubMed - indexed for MEDLINE]
7. [Recombinant single-chain immunotoxins against T and B cell leukemias.](#)
Kreitman RJ, Pastan I.
Leuk Lymphoma. 1994 Mar;13(1-2):1-10. Review.
PMID: 8025511 [PubMed - indexed for MEDLINE]
8. [Cytotoxicity of recombinant Fab and Fv immunotoxins on adult T-cell leukemia lymph node and blood cells in the presence of soluble interleukin-2 receptor.](#)
Saito T, Kreitman RJ, Hanada S, Makino T, Utsunomiya A, Sumizawa T, Arima T, Chang CN, Hudson D, Pastan I, et al.
Cancer Res. 1994 Feb 15;54(4):1059-64.
PMID: 8313362 [PubMed - indexed for MEDLINE]
9. [Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.](#)
Kreitman RJ, Chaudhary VK, Waldmann TA, Hanchard B, Cranston B, FitzGerald DJ, Pastan I.
Leukemia. 1993 Apr;7(4):553-62.
PMID: 8464234 [PubMed - indexed for MEDLINE]
10. [Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds.](#)
Kreitman RJ, Batra JK, Seetharam S, Chaudhary VK, FitzGerald DJ, Pastan I.
Bioconjug Chem. 1993 Mar-Apr;4(2):112-20.
PMID: 7873642 [PubMed - indexed for MEDLINE]
11. [Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia.](#)
Kreitman RJ, Chaudhary VK, Kozak RW, FitzGerald DJ, Waldman TA, Pastan I.
Blood. 1992 Nov 1;80(9):2344-52.
PMID: 1421405 [PubMed - indexed for MEDLINE] Free Article
12. [Mik-beta 1\(Fv\)-PE40, a recombinant immunotoxin cytotoxic toward cells bearing the beta-chain of the IL-2 receptor.](#)
Kreitman RJ, Schneider WP, Queen C, Tsudo M, Fitzgerald DJ, Waldmann TA, Pastan I.
J Immunol. 1992 Oct 15;149(8):2810-5.
PMID: 1401913 [PubMed - indexed for MEDLINE]